Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...

Immutep Expands Part B of TACTI-002 Study Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...

Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet), a wholly-owned subsidiary of the Medical Society of Delaware...